Silence Therapeutics Management
Management criteria checks 4/4
Silence Therapeutics' CEO is Iain Ross, appointed in Dec 2025, has a tenure of less than a year. directly owns 0.028% of the company’s shares, worth $92.81K. The average tenure of the management team and the board of directors is 2.3 years and 6.1 years respectively.
Key information
Iain Ross
Chief executive officer
US$482.1k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.03% |
| Management average tenure | 2.3yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive
Feb 05
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
Jan 31Silence Therapeutics: Divesiran Targets High-Burden PV
Nov 18Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
Oct 19Pinning Down Silence Therapeutics plc's (NASDAQ:SLN) P/S Is Difficult Right Now
Sep 28Newsflash: Silence Therapeutics plc (NASDAQ:SLN) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Silence Therapeutics plc (NASDAQ:SLN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 12Silence Therapeutics plc (NASDAQ:SLN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 11Silence Therapeutics plc's (NASDAQ:SLN) Price Is Right But Growth Is Lacking After Shares Rocket 50%
May 06
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments.Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Mar 22These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Mar 06We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Mar 04Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Jan 28Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Dec 10Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
Oct 04Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 18Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
Jun 17Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
May 21Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$89m |
| Sep 30 2025 | n/a | n/a | -US$65m |
| Jun 30 2025 | n/a | n/a | -US$79m |
| Mar 31 2025 | n/a | n/a | -US$72m |
| Dec 31 2024 | US$482k | n/a | -US$45m |
| Sep 30 2024 | n/a | n/a | -US$73m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$512k | n/a | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$53m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | US$673k | n/a | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$162k | n/a | -US$53m |
| Sep 30 2021 | n/a | n/a | -US$57m |
| Jun 30 2021 | n/a | n/a | -US$57m |
| Mar 31 2021 | n/a | n/a | -US$49m |
| Dec 31 2020 | US$2m | US$386k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$33m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$122k | US$121k | -US$26m |
Compensation vs Market: Iain's total compensation ($USD482.13K) is below average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Iain's compensation has been consistent with company performance over the past year.
CEO
Iain Ross (71 yo)
Mr. Iain Gladstone Ross, B. Sc (Hons) Biochemistry, C. DIR, CH. D., serves as Executive Chairman at Oxford BioDynamics Plc since 2025. He has been the Non-Executive Director of Tern Plc since October 29, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Chairman of the Board | less than a year | US$482.13k | 0.028% $ 92.8k | |
| Executive VP | 4.1yrs | US$1.66m | 0.0011% $ 3.5k | |
| Executive VP and Chief Research & Development Officer | 2.9yrs | US$1.59m | 0.0092% $ 30.2k | |
| Chief Scientific Officer | 2.3yrs | no data | no data | |
| Head of IR & Corporate Communications | no data | no data | no data | |
| SVP & General Counsel | less than a year | no data | no data | |
| Chief Human Resources Officer | 1.9yrs | no data | no data | |
| Chief Technical Operations Officer | 3.3yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
Experienced Management: SLN's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Chairman of the Board | 6.9yrs | US$482.13k | 0.028% $ 92.8k | |
| Executive VP | less than a year | US$1.66m | 0.0011% $ 3.5k | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.8yrs | US$216.07k | 0.0053% $ 17.5k | |
| Chairman of Scientific Advisory Board | 6.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.1yrs | no data | no data | |
| Director | less than a year | US$213.07k | 0.011% $ 34.8k | |
| Member of Scientific Advisory Board | 6.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data |
Experienced Board: SLN's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 14:18 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silence Therapeutics plc is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Keay Nakae | Chardan Capital Markets, LLC |
| Nathaniel Calloway | Edison Investment Research |